CytomX Therapeutics, Inc.
CTMX
Rank in Stocks
#12900
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company... CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Share Price
$1.98
Last synced: 2026-11-09
Market Cap
$431.44M
Change (1 day)
-9.59%
Change (1 year)
-51.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CytomX Therapeutics, Inc. (CTMX)
Category
Healthcare
Operating Margin for CytomX Therapeutics, Inc. (CTMX)
Operating Margin as of November 2026 TTM: -476.19%
According to CytomX Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -476.19%. At the end of 2025 the company had an operating margin of -29.35%.
Operating Margin history for CytomX Therapeutics, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -476.19% | 1,522.45% |
| 2025 | -29.35% | -262.15% |
| 2024 | 18.10% | -382.37% |
| 2023 | -6.41% | -96.64% |
| 2022 | -190.61% | -38.71% |
| 2021 | -311.00% | 164.23% |
| 2020 | -117.70% | -38.98% |
| 2019 | -192.90% | 47.39% |
| 2018 | -130.88% | 102.63% |
| 2017 | -64.59% | -83.69% |
| 2016 | -396.10% | -8.00% |
| 2015 | -430.54% | -26.56% |
| 2014 | -586.27% | -65.19% |
| 2013 | -1,684.23% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.08% |
US
|
|
| -149.01% | -99.69% |
US
|
|
| 25.57% | -100.05% |
AU
|
|
| 31.23% | -100.07% |
BE
|
|
| 29.35% | -100.06% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about CytomX Therapeutics, Inc.'s operating margin
What is CytomX Therapeutics, Inc.'s operating margin?
CytomX Therapeutics, Inc.'s operating margin is -476.19%, as of Nov 2026.
What was CytomX Therapeutics, Inc.'s operating margin in 2025?
In 2025, CytomX Therapeutics, Inc.'s operating margin was -29.35%, compared with 18.10% in 2024.
How has CytomX Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, CytomX Therapeutics, Inc.'s operating margin was highest in 2024 (18.10%) and lowest in 2021 (-311.00%).
How does CytomX Therapeutics, Inc.'s operating margin compare with similar companies?
CytomX Therapeutics, Inc.'s operating margin (-476.19%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.